Clinical data for Episealer® accepted for presentation at German scientific congress
Episurf Medical (Nasdaq: EPIS B) today announces that the scientific abstract “The bi- and tri-compartmentalized patient-specific mini-surface replacement for the treatment of therapy-resistant focal (osteo-) chondral knee joint lesions of the middle-aged patient - short term clinical results.” by Priv.-Doz. Dr. med. Clemens Kösters will be presented at the AGA 36th annual congress in Mannheim, Germany, which will take place on October 12-14, 2019. The abstract presents short term clinical results after bi- and tricompartmental implantation of Episealer® knee implants in middle-aged patients.
The abstract concludes that the treatment gap for middle-aged patients with focal (osteo) chondral lesions can be closed, at least in the short-term, and possibly endoprosthesis implantation may be delayed or avoided.
"Patients with multiple lesions are in no way uncommon for us, but the cases are often quite complex. The positive results are very encouraging, and the conclusions in the abstract are really interesting”, says Pål Ryfors, CEO of Episurf Medical.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
Tags: